# Filing Detail

Form ARS - Annual Report to Security Holders:
SEC Accession No. 0001193125-26-168538
Filing Date
2026-04-22
Accepted
2026-04-22 08:04:25
Documents
1
Period of Report
2025-12-31
Effectiveness Date
2026-04-22

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | ARS | d942601dars.pdf | ARS | 8781844
| Complete submission text file | 0001193125-26-168538.txt |  | 12068726

Mailing Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247
Business Address 3000 PEGASUS PARK DRIVE SUITE 1430 DALLAS TX 75247 (214) 612-0000
Taysha Gene Therapies, Inc. (Filer) CIK: 0001806310 (see all company filings)

EIN.: 843199512 | State of Incorp.: DE | Fiscal Year End: 1231
Type: ARS | Act: 34 | File No.: 001-39536 | Film No.: 26881331
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)